Seagen to highlight two novel antibody-drug conjugates (adcs) at the sitc 36th annual meeting

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen), today announced the presentation of two new vedotin-based antibody-drug conjugate (adc) programs at the society for immunotherapy of cancer (sitc) 36th anniversary annual meeting, taking place in washington, d.c. and virtually, november 10-14, 2021. each program combines antibodies targeted to an immune checkpoint [pd-(l)1 or b7-h4] with the cytotoxic properties of the vedotin payload. preclinical data demonstrate promising antitumor a
SGEN Ratings Summary
SGEN Quant Ranking